Vaccines do work for pandemic flu, says study

March 13, 2017
Credit: National Cancer Institute

Vaccines are successful in preventing pandemic flu and reducing the number of patients hospitalised as a result of the illness, a study led by academics at The University of Nottingham has found.

However, the research - the most comprehensive review undertaken in this area - also found that the effectiveness of vaccines can vary depending on the age of the patient.

The work, published in the journal Vaccine, was led by Professor Jonathan Van Tam and Dr Louise Lansbury in the University's Health Protection and Influenza Research Group in collaboration with other scientists in the UK, Japan, Bosnia and the Netherlands.

Professor Van Tam said: ""The 2009 swine flu pandemic was the first in human history when pandemic vaccines have been available worldwide. It's therefore really important to pull all of these data together and ask the question: did these vaccines really work?

"We found that the vaccines produced against the swine flu pandemic in 2009 were very effective in both preventing influenza infection and reducing the chances of hospital admission due to flu. This is all very encouraging in case we encounter a future pandemic, perhaps one that is more severe. Of course, we recognise that it took five to six months for pandemic vaccines to be ready in large quantities; this was a separate problem. However, if we can speed up production times, we would have a very effective strategy to reduce the impact of a future ."

In early 2009, a novel influenza A(H1N1) virus appeared in humans, containing a unique combination of influenza genes which had not previously been identified in animals or people. The first cases were reported in the United States in March 2009 but the new virus spread rapidly to other countries and in June 2009 the WHO declared a pandemic caused by this strain, known as influenza A(H1N1)pdm09, or 'swine flu'.

An estimated 61 million people were infected worldwide. Vaccines against the new strain were developed and rolled out across the world from September to December 2009. The majority of vaccines available contained inactivated A(H1N1)pdm09 influenza virus rather than live virus. Some formulations also contained an 'adjuvant' to strengthen the body's immune response to the vaccine and allow smaller doses of antigen to be used (adjuvanted vaccines).

Many individual studies have looked at how effective the available vaccines were at preventing illness and hospitalisation caused by the pandemic influenza strain but up until now no-one has summarised all the available data. This systematic review and meta-analysis is the most comprehensive summary and offers insight into the relative effectiveness of both adjuvanted and non-adjuvanted vaccines in different age groups.

The researchers found 38 studies published between June 2011 and April 2016 that measured the effectiveness of the inactivated pandemic influenza vaccines, covering a population of more than 7.6m people. Twenty-three of these studies reported results that were suitable for meta-analysis - a statistical method used to combine the results from multiple individual studies that are broadly similar in terms of vaccine used and types of people in the study and which is statistically more powerful and can provide a more precise estimate of the effect of vaccination than any individual study contributing to the analysis.

Overall, pandemic influenza vaccines were found to be 73 per cent effective at preventing laboratory-confirmed influenza illness and 61 per cent effective at preventing hospitalisation in the population as a whole. However, when the vaccines' effectiveness was examined in different age groups, they were shown to be less effective in adults over 18 years than in children, and effectiveness was lowest in adults over 50 years of age. Adjuvanted vaccines in particular were found to be more effective in children than in adults against laboratory confirmed illness (88 per cent in children versus 40 per cent in adults) and hospitalisation (86 per cent in children versus 48 per cent in adults).

Overall the inactivated pandemic used in the 2009 pandemic were effective in preventing laboratory-confirmed illness and hospitalisation. Adjuvanted vaccines tended to be more effective than non-adjuvanted vaccines but only in children. The lower effectiveness in older people may be due to them having pre-existing antibodies against A(H1N1)pdm09 from previous exposure to a similar virus, with corresponding lower incidence of the infection in this age group.

The results showed that vaccines produced globally during the 2009-10 pandemic were largely effective in reducing illness and hospitalisation. The results from the study could be used to help public health officials to plan a more effective response to future pandemics, such as rolling out vaccines at a much earlier time and targeting specific types of vaccines at different .

Explore further: Key benefits of large-scale use of universal over conventional flu vaccines

More information: Vaccine, DOI: 10.1016/j.vaccine.2017.02.05

Related Stories

Key benefits of large-scale use of universal over conventional flu vaccines

December 15, 2016
Universal vaccines that protect against multiple strains of influenza virus at once could offer key population-level benefits over conventional seasonal vaccines, according to a new study published in PLOS Computational Biology.

No substantial link between swine flu vaccine and Guillain-Barre syndrome, confirm experts

July 13, 2011
Adjuvanted vaccines used during the 2009 swine flu pandemic did not increase the risk of Guillain-Barré syndrome substantially, if at all, finds a large Europe-wide study published in the British Medical Journal today. ...

UGA, Sanofi Pasteur develop new vaccine for H1N1 influenza

March 29, 2016
Researchers at the University of Georgia and Sanofi Pasteur, the vaccines division of Sanofi, announced today the development of a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza ...

Prime-boost H7N9 influenza vaccine concept promising in clinical trial

December 10, 2015
In clinical trials, several candidate H7N9 pandemic influenza vaccines made from inactivated viruses have been shown to be safe and to generate an immune response. However, scientists believe for practical use, these potential ...

Recommended for you

Portable 3-D scanner assesses patients with elephantiasis

October 17, 2017
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis. Health-care ...

New tools to combat kidney fibrosis

October 16, 2017
Interstitial fibrosis – excessive tissue scarring – contributes to chronic kidney disease, which is increasing in prevalence in the United States.

How hepatitis C hides in the body

October 13, 2017
The Hepatitis C (HCV) virus is a sly enemy to have in one's body. Not only does it manage to make itself invisible to the immune system by breaking down communication between the immune cells, it also builds secret virus ...

Largest study yet of malaria in Africa shows historical rates of infection

October 12, 2017
(Medical Xpress)—A team of researchers with members from the Kenya Medical Research Institute, the University of Oxford and the University of KwaZulu-Natal has conducted the largest-ever study of the history of malaria ...

Promising new target for treatment of psoriasis is safe, study shows

October 11, 2017
A protein known to play a significant role in the development of psoriasis can be prevented from functioning without posing a risk to patients, scientists at King's College London have found.

Norovirus evades immune system by hiding out in rare gut cells

October 11, 2017
Noroviruses are the leading cause of non-bacterial gastroenteritis in the world and are estimated to cause 267 million infections and 20,000 deaths each year. This virus causes severe diarrhea, nausea, and stomach pain.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.